Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages

5 Jun 2025

Abstract excerpt

BACKGROUND AND OBJECTIVES: Phosphorylated tau at threonine 217 (p-tau217) is a highly sensitive blood-based biomarker for Alzheimer disease (AD) pathology, showing high diagnostic accuracy. However, its prognostic value across different clinical stages of AD remains unclear. The aim of this study was to assess the prognostic utility of plasma p-tau217, measured using a commercially available immunoassay,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Neurological Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40472304
DOI: 10.1212/wnl.0000000000213769

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesPMID 40472304Read ↗

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity Read ↗

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity Read ↗

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity Read ↗

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read ↗

Cross-sectional study of plasma phosphorylated Tau 217 in persons without dementiaSemantic proximity Read ↗

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read ↗

Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity Read ↗

Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individualsSemantic proximity Read ↗

Predicting Preclinical Cognitive Decline Using Plasma P-tau217 and <i>APOE</i> Genotype in 8,582 Individuals From Different Ethnic GroupsSemantic proximity Read ↗

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read ↗

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read ↗

Clinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.